OBJECTIVE	The antidepressant , agomelatine , which acts as an agonist at melatonin MT ( 1 ) and MT ( 2 ) receptors and as an antagonist at serotonin 5-HT ( 2C ) receptors , has demonstrated efficacy and safety in both major depression and generalized anxiety disorder .\